When a jazz group improvises, the music works only because the players share an underlying framework. They agree on the tune, the feel, and the general chord structure. That shared foundation gives each musician room to explore. The harmony comes not from uniformity, but from alignment.
Clinical guidelines should play a similar role in medicine. Medical societies and expert panels synthesize evidence to guide appropriate use of diagnostics and treatments across diverse clinical settings. Payers rely on guidelines when shaping coverage criteria, and clinicians rely on them to guide patient care. These documents typically address clinical effectiveness without directly evaluating cost effectiveness. That omission creates a structural divide: guidelines point in one direction, while payers must make resource-aware decisions that guidelines do not address. Misalignment follows.
The standard approach: clinical benefit without economic context
Most medical society guidelines in the United States focus solely on clinical performance — how well therapies work, how safe they are, and the strength of the supporting evidence. This reflects a longstanding convention: Guidelines committees view economic evaluation as outside their scope. But the absence of cost-effectiveness considerations has predictable consequences:
- Guidelines implicitly treat therapies as if cost does not matter, even for unusually costly therapies or when ongoing therapies consume large shares of health plan budgets
- Payers must independently assess economic value when determining coverage, applying criteria that guidelines never considered
- Clinicians interpret payer decisions as financial constraints rather than evidence-based judgment
- Patients encounter inconsistent coverage policies across payers, driven not by differing clinical views but by differing economic assessments
No group is at fault here. Guideline committees focus on clinical science; payers must ensure affordable access. Each is doing its job — but without shared criteria, their decisions diverge.
Emerging models: where clinical and economic judgment converge
Although U.S. guideline committees rarely directly incorporate cost-effectiveness, a few influential groups show that integrated evaluation is possible.
The American College of Cardiology/American Heart Association value framework pairs traditional clinical recommendations with transparent economic assessments. For instance, it assigns a separate value rating (high, intermediate, or low) by comparing the clinical benefit to the estimated cost, creating an explicit framework for evaluating whether a treatment is worth its resource use. ASCO has also advanced the conversation through its work on financial toxicity and treatment value frameworks. While these are not full cost-effectiveness analyses, they acknowledge the economic burden of cancer treatments and are intended to help clinicians consider affordability when discussing treatment options with patients. These examples demonstrate that medical societies can bring clinical and economic rigor together if they choose to.
How the gap affects care delivery
When guidelines address only clinical outcomes, payers must supply the economic dimension through utilization management tools:
- Prior authorization
- Step therapy requirements
- Quantity and duration limits
- Coverage exclusions
These measures are not designed to contradict clinical guidance but to supply the missing cost-effectiveness assessment that guidelines seldom perform. From clinicians’ perspective, these utilization controls often feel like arbitrary barriers. When a guideline endorses a therapy as clinically superior, and a payer then imposes prior authorization or step therapy, the clinician views this not as a resource-aware decision, but as a purely financial veto. This friction erodes trust in the system and adds massive administrative burden, as clinicians are forced to spend time justifying a clinical decision that their own guidelines already endorsed.
For patients, this structural divide translates into inconsistent coverage. A patient’s access to a new expensive cancer immunotherapy may depend less on the drug’s proven clinical benefit and more on which payer’s specific economic assessment determines the policy — creating seemingly arbitrary differences in access between Medicare Advantage, employer plans, and state Medicaid programs. Ignoring cost does not protect patients; it simply shifts difficult economic decisions downstream, where they reappear as utilization management and inconsistent access across payers. Because guidelines do not address value, coverage criteria and guidelines frequently diverge — not because one side disagrees with the other clinically, but because only one side is responsible for evaluating cost.
Why integrated value assessment is becoming essential
The economics of modern therapeutics — particularly in oncology, rare disease, and gene therapies — make the separation between clinical and economic evaluation untenable. Many new therapies are priced at levels that force difficult tradeoffs. Without assessing value, guidelines cannot answer the question patients and payers must ultimately confront: Is this therapy worth its cost?
Embedding cost-effectiveness assessments into guidelines would deliver several benefits:
- Greater legitimacy: When medical societies acknowledge economic value directly, payers’ coverage decisions better reflect clinical consensus rather than appearing financially motivated
- Clearer alignment: Value-based recommendations allow payers to adopt guideline criteria with fewer modifications, reducing denial rates and appeals while improving administrative efficiency for both health plans and providers
- Better resource stewardship: High-value therapies become easier to access; low-value therapies face justified scrutiny
- Improved transparency: Clinicians and patients better understand why coverage criteria look the way they do
Cost-effectiveness analyses do not undermine clinical autonomy. Instead, it gives clinicians and payers more complete information by clarifying when a therapy’s price aligns with its expected benefit — information both clinicians and payers need.
What medical societies can do
Medical societies do not need to become full health-technology assessment agencies, but they can meaningfully narrow the payer-provider gap through practical steps:
- Incorporate economic value into guideline scopes when evidence and pricing allow
- Provide value ratings or tiers alongside clinical ratings
- Draw on external cost-effectiveness analyses — particularly transparent, methodologically consistent evaluations like those produced by the Institute for Clinical and Economic Review — as reference points
- Make cost-effectiveness expertise part of guideline-writing committees
- Offer sequence or pathway recommendations grounded in both clinical evidence and value
If medical societies adopt even some of these elements, they can create guidance that is clinically rigorous, economically informed, and far easier for payers to implement without additional restrictions.
The path forward
The most effective way to reduce payer-provider friction is not to remove cost considerations from coverage decisions, but to integrate them earlier — within the guidelines that shape clinical practice.
When guideline developers incorporate cost-effectiveness directly into their recommendations, they create a shared evidentiary foundation that clinicians trust and payers can use without extensive modification. Improving alignment does not require diminishing clinical judgment. It requires expanding the definition of responsible guidance to include value.
By embracing value as a legitimate dimension of clinical recommendations, medical societies create guidelines that support both clinical excellence and sustainable access. In jazz, improvisation works because everyone plays from the same underlying structure. When clinical evidence and economic value rest on the same foundation, clinicians and payers can move more harmoniously toward their shared goal of delivering high-quality, affordable care to patients.
No Comments